Roche moves SC against Natco over Risdiplam sale in India

Swiss drugmaker Roche has moved the Supreme Court, seeking to restrain Natco Pharma from selling the generic version of its lifesaving spinal muscular atrophy (SMA) drug Risdiplam in India.

- Krishna Yadav & Jessica Jani

Roche holds an Indian patent for Risdiplam, valid from May 2015 to May 2035.

(REUTER)

Roche approached the apex court after the Delhi High Court division bench on 9 October refused to bar Natco Pharma from selling the generic version, upholding a March single-judge order that denied Roche an injunction.

The plea for urgent listing wasmentioned on Tuesday by Roche’scounsel beforea bench led by chief justice B.R. Gavai, which agreed to hear the matteron Thursday or Friday.